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Introduction
In high-income countries, life expectancy of people living with 
HIV (PLWHIV) on combination antiretroviral therapy (cART) 
is approaching that of the general population1. For example, 
in Switzerland 2006 to 2013, PLWHIV with higher educa-
tion had an estimated life expectancy similar to individuals 
from the general population with compulsory education2. Simi-
larly, in Canada 2008 to 2012, life expectancy at age 20 years 
in HIV-positive people was 89% of the life expectancy in 
the general population3. In line with the increasing life expect-
ancy, morbidity and mortality of PLWHIV on cART are no 
longer dominated by AIDS-defining events, but also affected 
by cardiovascular events and non-AIDS defining malignancies 
(NADM)1–5.
An analysis of causes of death in the Data collection on Adverse 
events of Anti-HIV Drugs (a collaboration of eleven HIV 
cohort studies from Europe, the USA and Australia), found that 
mortality decreased from 1999 to 2011 for most causes of 
death, including AIDS-related, liver-related, cardiovascular and 
other or unknown causes4. However, in this collaborative study4 
and in other cohorts5–7, mortality from NADM remained stable 
over time. This type of cancer is now the most common cause 
of non-AIDS deaths in PLWHIV in high-income countries8. 
Furthermore, compared to the general population, the inci-
dence of NADM is increased in PLWHIV, with a standardized 
incidence ratio for all NADM combined ranging from 1.6 to 
2.8 across different studies9.
Several factors contribute to the higher risk of NADM among 
HIV-positive individuals, including prolonged exposure to immu-
nodeficiency, a higher prevalence of smoking, and infections 
with oncogenic viruses such as human papilloma virus (HPV) 
or hepatitis B (HBV) or hepatitis C (HCV) viruses10–12. Direct 
pro-oncogenic effects of HIV, inflammation, and coagulation 
pathways may also play a role13,14. More recently, accelerated 
immune senescence, as evidenced by low ratios of CD4 to CD8 
positive T cells (CD4/CD8 ratio), has been identified as a poten-
tial risk factor for NADM15,16. For example, in the US Veterans 
Aging Cohort Study, the CD4/CD8 ratio, but not the CD4 
cell count, was an independent risk factor for lung cancer15.
We linked the database of the Swiss HIV Cohort Study 
(SHCS) with cantonal cancer registries to examine the rela-
tive importance of different risk factors for NADM, including 
immunological, virological and socio-behavioral factors.
Methods
The Swiss HIV Cohort Study
The SHCS is an ongoing observational study that promotes clini-
cal and public health research on HIV in Switzerland17,18. The 
SHCS is a collaboration between various hospitals, clinics, labo-
ratories, and private practices across the country. Prospective 
enrollment started in 1988, and involves PLWHIV aged 16 years 
or above. Detailed socio-demographic and behavioral parameters 
for each patient are collected at enrollment. Laboratory results 
such as CD4+ and CD8+ cell count, HIV-1 RNA viral load 
or indicators of exposure to hepatitis B or C virus are recorded 
at enrollment and during follow-up visits. Detailed infor-
mation on ART and other treatments, and of AIDS defining 
events are also collected at regular intervals. While NADM are 
recorded in the study, their ascertainment is incomplete.
Linkage to cancer registries
Incident cancers in the SHCS were identified through link-
age of SHCS records with the records of the Basel, Geneva, 
and Zurich cantonal cancer registries. At the time of the link-
age, the data covered the period up to 2012 for Geneva and 
Zurich, and 2011 for Basel. Only SHCS participants registered 
in the areas covered by the three aforementioned cancer regis-
tries were included, representing about 65% of all participants. 
The linkage was done using privacy-preserving probabilistic 
record linkage19,20. Briefly, we employed a three-party protocol, 
with the SHCS and cancer registries collecting confidential 
individual-level patient data and the Institute of Social and Pre-
ventive Medicine at University of Bern serving as the independent 
linkage center. The linkage center supplied purpose-written 
encryption software21 that was used at SHCS centers and cancer 
registries to irreversibly encrypt personal identifying data 
(names, date of birth) using Bloom filters and calculate the simi-
larity coefficients, which were then used to identify matching 
records at ISPM.
Cancers included in analyses
We supplemented the cancer cases reported in the SHCS by 
the cases identified through data linkage. We analyzed NADM 
classified according to the 10th revision of the International 
Classification of Diseases (ICD-10) that were diagnosed in about 
40 or more patients: malignant neoplasm of anus and anal canal 
(C21), malignant neoplasm of liver and intrahepatic bile ducts 
(C22, excludes malignant neoplasm of other and unspecified 
parts of biliary tract), malignant neoplasm of trachea, bron-
chus and lung (C33–34), and prostate cancer (C61). We did not 
include Hodgkin lymphoma because most cases had been diag-
nosed in the early years of cART, when CD8 counts and viral load 
measurements were often missing.
Standardized incidence ratios
We calculated standardized incidence ratios (SIRs) for each 
identified NADM by comparing the observed number of 
cancers among people with HIV with the expected number of 
occurrences, based on age-, sex- and period-specific rates for the 
Swiss population provided by the National Institute for Cancer 
Epidemiology and Registration (indirect standardization)22. We 
produced 95% confidence intervals (CI) for the SIRs assuming a 
Poisson distribution23.
Baseline and time-updated exposure variables
We assessed the effect of baseline and time-updated exposure 
variables in Cox regression models. Time-updated variables 
included CD4 cell count (cells/µL), CD8 cell count (cells/µL), 
CD4/CD8 ratio and HIV viral load (copies/mL). We updated 
the immunological and virological factors at the start of each 
month. Months with no CD4 cell count, CD8 cell count, or HIV 
viral load were interpolated by carrying forward or carrying back 
the closest measured value within 12 months, provided there 
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was no change in cART and no diagnosis of cancer in the inter-
val. Time-updated bacterial pneumonia was additionally con-
sidered for lung cancer: history of bacterial pneumonia changed 
from no to yes when pneumonia was diagnosed. Other vari-
ables included age, likely HIV transmission group (men having 
sex with men [MSM], intravenous drug users [IDU], other men, 
other women), current smoking at enrollment (yes, no), highest 
completed level of education (compulsory, secondary, terti-
ary), chronic hepatitis B and exposure to hepatitis C (yes or no, 
as a time-updated variable), and calendar period (time-updated; 
before 2002, 2002–2007, 2008 and later). Patients were defined 
as having chronic hepatitis B if they had previously been tested 
positive for HBs-antigen or HBV-DNA, and as being exposed 
to hepatitis C during follow-up if they had tested positive 
for HCV-RNA.
Statistical analyses
We used Cox regression models for time to event analyses, 
measuring time from enrollment to the diagnosis of a NADM, 
the last clinic visit in the study period, or death, whichever 
came first. Follow-up time in patients enrolled before 1996, the 
year cART was introduced, was left truncated at 31 December 
1995. Patients diagnosed with a NADM before 1 January 1996 
were excluded from the analysis for that specific NADM.
In a first step, we modeled the association of the time-updated 
immunological and virological exposure variables (CD4 cell 
count, CD8 cell count, CD4/CD8 ratio, and HIV viral load) with 
each of the four cancers separately, adjusting for the other vari-
ables. To reduce the risk of detecting associations that reflect 
reverse causality, we lagged these variables for 12 months or 
more, and captured cumulative exposure using simple moving 
averages (SMA). We entered the following representations 
of each variable: lagged by 12, 24 or 36 months; SMA over 
12 months - lagged by 12 or 24 months; SMA over 24 months 
- lagged by 12 months (see Figure 1). In a next step we selected 
variables and representations of variables for inclusion into a 
final, malignancy-specific model. We selected one representa-
tion of each immunological and virological variable based on 
the goodness of fit (indexed by the Akaike information criteria 
[AIC]) and carried over variables significantly associated with 
cancer incidence (P <0.05) when modeled separately. The inter-
mediary and final models were adjusted for the variables age, 
transmission group, smoking, education, chronic hepatitis 
B, exposure to hepatitis C, and calendar period. The time-updated 
variables for bacterial pneumonia (used only in the lung cancer 
analysis), hepatitis B, and hepatitis C were lagged by 12 months.
We assessed proportionality assumptions of the Cox model using 
the Schoenfeld residuals. Results are shown as hazard ratios 
(HR) with 95% confidence intervals (95% CI). We imputed 
missing values for smoking using multivariate imputation by 
chained equations and pooled results of five imputed dataset. We 
present the analyses with imputation since results were similar to 
complete-case analyses. All analyses were done in R Project for 
Statistical Computing (version 3.6.0) software24 using pack-
ages survival (version 2.42), mice (version 3.30) and mitools 
(version 2.3). R code and explanatory documents are available as 
extended data25.
Results
Incidence and patient characteristics
A total of 563 incident NADM were identified in the two data 
sources (SHCS and cancer registries). The SHCS recorded 
60.9% of all cases, and the registries 76.2%. For the cancers 
analyzed in this study, the completeness of recording of cases 
Figure 1. Schematic representation of simple moving averages (SMAs), lagged over different periods.
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in the SHCS was 54.3% for anal cancer, 66.7% for liver cancer, 
71.4% for lung cancer, and 72.7% for prostate cancer. The 
corresponding percentages for the cancer registries were 85.7%, 
80.6%, 85.7% and 93.2%, respectively (Table 1).
Anal cancer was diagnosed in 70 patients over 71,592 person- 
years for an incidence rate of 9.78 per 10,000 person-years 
(95% confidence interval [CI] 7.62-12.35). Lung cancer was 
diagnosed in 49 patients over 71,888 person-years (6.82 per 
10,000; 95% CI 5.04-9.01), prostate cancer in 44 men over 
50,322 person-years (8.74 per 10,000; 95% CI 6.35-11.74), and liver 
cancer in 36 patients over 71,911 person-years (5.01 per 10,000; 
95% CI 3.51-6.93).
Compared to the Swiss general population, anal, lung, and 
liver cancer all exhibited higher rates in the SHCS, whereas 
the rate of prostate cancer was similar (Figure 2). The differ-
ence was largest for anal cancer: the incidence was 76 times 
higher in people with HIV (SIR 76.1, 95% CI 60.2-96.2) than 
in the general Swiss population.
Characteristics of SHCS participants who developed cancer 
and participants who did not are shown in Table 2. Compared 
to those who remained free of cancer, HIV-positive individu-
als, who developed cancer were slightly older, more likely to be 
smokers, and at a more advanced clinical stage of HIV infection 
according to the Centers for Disease Control and Prevention 
classification26. The distribution across HIV transmission 
groups also varied between cancers: the majority of patients 
who developed anal or prostate cancer were MSM, while those 
with lung or liver cancer were predominantly patients with a 
history of IDU.
Immunological and socio-behavioral risk factors
We selected one representation of each exposure variable based 
on goodness of fit models. The AIC values for the different 
models are shown in Table 3, the results of the separate models 
for each immunological and virological variable in Table 4 and 
the results of the mutually adjusted models in Table 5. For anal 
cancer, CD4 count, CD8 count and CD4/CD8 ratio were all 
associated with cancer risk in the separate models (Table 4). In 
the mutually adjusted model, a higher CD4 cell count (lagged 
12 months) and a CD8 count below 1000 cells/µl (lagged by 
24 months) continued to be significantly associated (P=0.002) 
with a reduced risk of anal cancer (Table 5). For example, in 
patients with a 12-month lagged CD4 count above 500 cells/µl, 
risk was reduced to about a fourth compared to individuals with 
a CD4 count below 200 cells/µl (hazard ratio [HR] 0.24; 95% 
CI 0.10-0.61). The risk of anal cancer was substantially higher 
in MSM (HR 6.86, 95% CI 1.64-28.6) than other men and 
higher in smokers (HR 2.07, 95% CI 1.07-3.98) compared 
to non-smokers.
Table 1. Number of individuals enrolled in the SHCS who developed a non-AIDS defining malignancy as identified through 
linkage to cancer registries or reported in the Swiss HIV Cohort Study (SHCS), 1996 to 2012.
Non AIDS Defining 
Malignancy (NADM)
Number of cases 
identified through 
linkage and in SHCS





in SHCS only (b)




Anus 28 32 10 70 54.3 85.7
Lung 28 14 7 49 71.4 85.7
Prostate 29 12 3 44 72.7 93.2
Liver 17 12 7 36 66.7 80.6
Head and neck 7 23 2 32 28.1 93.8
Hodgkin Lymphoma 23 7 7 37 81.1 81.1
Bladder 3 9 0 12 25.0 100
Breast 9 3 4 16 81.3 75.0
Colon and Rectum 6 2 5 13 84.6 61.5
Kidney 5 0 4 9 100 55.6
Oesophagus 4 0 4 8 100 50.0
Skin Melanoma 6 13 5 24 45.8 79.2
Stomach 3 1 3 7 85.7 57.1
Testis 6 1 1 8 87.5 87.5
Other NADM 35 91 72 198 54.0 63.6
All NADM 209 220 124 563 60.9 76.2
* calculated as (c-a)/c
& calculated as (c-b)/c
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For lung cancer and prostate cancer, Cox regression models 
were stratified by age to preserve proportional hazards. In the 
case of lung cancer, CD8 cell count (lagged by 36 months) was 
the only significant predictor (P=0.04) among the immuno-
logical and virological variables (Table 2): participants with 
CD8 cell counts equal to or above 1000 cells/µl had a greater 
risk of developing lung cancer, compared to those with counts 
below 1000 cells/µl (HR 1.89, 95% CI 1.03-3.48). A history of 
bacterial pneumonia was associated with lung cancer in the 
separate model (Table 4), but not after adjusting for CD8 cell 
count (Table 5). Smoking at enrollment was strongly associ-
ated with lung cancer (HR 6.50, 95% CI 1.36-31.2, Table 5). For 
prostate cancer, none of the immunological or virological were 
associated with a risk of cancer (Table 4), though there was 
some evidence of smoking being associated with higher rates 
(HR 1.92, 95% CI 0.96-3.83, Table 5).
For liver cancer, exposure to lower CD4 counts (SMA over 
24 months, lagged by 12 months) and the CD4/CD8 ratio 
(lagged by 24 months) were associated with cancer incidence 
in the separate models (Table 4). In the final model (Table 5), 
only the CD4 cell count was predictive, with patients with 
average counts of 500 cells/µl or above at much lower risk 
than patients with counts below 200 cells/µL (HR 0.07, 95% 
CI 0.01-0.59). Chronic hepatitis B infection (HR 7.86, 95% 
CI 3.78-16.4) and hepatitis C infection (HR 4.77, 95% 
CI 1.80-12.7) were both strongly associated with liver cancer 
(Table 5).
Discussion
In the era of cART, life expectancy of PLWHIV is approach-
ing that of the general population, the incidence of 
AIDS-defining malignancies has declined sharply, and NADM 
have emerged as an important co-morbidity1,2,27,28. This study linked 
the database of the SHCS with three cantonal cancer registries to 
identify incident NADM. Anal, lung, prostate and liver cancers 
were common NADM among participants of SHCS. Compared to 
the general population, three of the four cancers occurred 
more frequently among PLWHIV. The exception was prostate 
cancer, whose incidence was similar to the general popula-
tion. Associations of lagged and cumulative exposure to immu-
nodeficiency or immune senescence were evident for some but 
not all cancers, and HIV replication was not related to cancer 
risk.
The SHCS is a well-established cohort of people living with 
HIV in Switzerland, where regular follow-up visits provide 
a wealth of information to inform fundamental, clinical and 
epidemiological research17,18. Both genders and the various 
transmission groups are well represented. We used state-of-the-
art privacy preserving linkage to complement incident cancers 
recorded in the SHCS with cases from cantonal registries19,20. 
Interestingly, neither the SHCS nor the cancer registries had a 
complete record of cases. This situation should improve in the near 
future, with the introduction of nationwide, compulsory cancer 
registration in Switzerland in 202029. Previous analyses of can-
cer risk in the SHCS used a matched case-control approach, 
which precluded the study of some risk factors30,31. For exam-
ple, matching cancer cases and controls on transmission group 
hampered the evaluation of hepatitis virus infections for liver 
cancer31, or of smoking for anal cancer32. Our study also has limi-
tations. Cancer linkage was only possible for three cantonal reg-
istries, which meant that about 35% of SHCS participants could 
not be included, limiting statistical power. Anal intercourse is 
Figure 2. The number of observed and expected incident cancer cases and standardized incidence ratios for non-AIDS defining 
malignancies (NADM) diagnosed among participants of the Swiss HIV Cohort Study.
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Table 2. Characteristics of HIV patients who developed non-AIDS defining malignancies (NADM) and who remained free of 
cancer.
Anal cancer Lung cancer Prostate cancer Liver cancer Other NADM Free of cancer
No. of patients 70 49 44 36 315 6696
Age, mean (SD) 46.71 (8.72) 49.98 (7.71) 62.23 (7.78) 48.28 (8.41) 49.77 (10.67) 44.71 (10.51)
Female (%) 11 (15.7) 15 (30.6) 0 4 (11.1) 97 (30.8) 1980 (29.6) 
Transmission group (%)
   MSM 52 (74.3) 14 (28.6) 28 (63.6) 13 (36.1) 116 (36.8) 2473 (36.9) 
   IDU 6 (8.6) 20 (40.8) 1 (2.3) 17 (47.2) 67 (21.3) 1675 (25.0) 
   Other men 3 (4.3) 6 (12.2) 15 (34.1) 6 (16.7) 68 (21.6) 1171 (17.5) 
   Other women 9 (12.9) 9 (18.4) 0 (0.0) 0 (0.0) 64 (20.3) 1377 (20.6) 
cART >6 months (%) 61 (87.1) 37 (75.5) 36 (81.8) 27 (75.0) 239 (75.9) 5410 (80.8) 
CD4 count [cells/µL] (%)
   0-199 12 (17.1) 5 (10.2) 5 (11.4) 8 (22.2) 60 (19.0)    742 (11.1) 
   200-349 16 (22.9) 12 (24.5) 11 (25.0) 14 (38.9) 49 (15.6)    825 (12.3) 
   350-499 13 (18.6) 11 (22.5) 7 (15.9) 11 (30.6) 64 (20.03) 1252 (18.7) 
   500+ 18 (25.7) 11 (22.5) 16 (36.4) 1 (2.8) 99 (31.4) 3130 (46.7) 
   Missing 11 (15.7) 10 (20.4) 5 (11.4) 2 (5.6) 43 (13.7)    747 (11.2) 
CD8 count [cells/µL] (%)
   0-999 30 (42.9) 25 (51.0) 24 (54.6) 27 (75.0) 184 (58.4) 4259 (63.6) 
   ≥1000 29 (41.4) 14 (28.6) 15 (34.1) 7 (19.4) 88 (27.9) 1665 (24.9) 
   Missing 11 (15.7) 10 (20.4) 5 (11.4) 2 (5.6) 43 (13.7)    772 (11.5) 
CD4/CD8 ratio (%)
   0-0.49 43 (61.4) 23 (46.9) 21 (47.7) 22 (61.1) 141 (44.8) 1928 (28.8) 
   0.5-1 13 (18.6) 13 (26.5) 10 (22.7) 7 (19.4) 93 (29.5) 2557 (38.2) 
   ≥1 3 (4.3) 3 (6.1) 8 (18.2) 5 (13.9) 38 (12.1) 1439 (21.5) 
   Missing 11 (15.7) 10 (20.4) 5 (11.4) 2 (5.6) 43 (13.7)    772 (11.5) 
RNA viral load [copies/mL]
   0-49 43 (61.4) 23 (46.9) 25 (56.8) 23 (63.9) 188 (59.7) 4409 (65.8) 
   50-499 8 (11.4) 7 (14.3) 8 (18.2) 5 (13.9) 33 (10.5)    506 (7.6) 
   ≥500 9 (12.9) 8 (16.3) 5 (11.4) 6 (16.7) 51 (16.2)    961 (14.4) 
   Missing 10 (14.3) 11 (22.4) 6 (13.6) 2 (5.6) 43 (13.7)    820 (12.2) 
Smoking at enrollment (%)
   Never 14 (20.0) 2 (4.1) 11 (25.0) 5 (13.9) 82 (26.0) 1998 (29.8) 
   Ever/current 53 (75.7) 40 (81.6) 30 (68.2) 26 (72.2) 203 (64.4) 3849 (57.5) 
   Missing 3 (4.3) 7 (14.3) 3 (6.8) 5 (13.9) 30 (9.5)    849 (12.7) 
Education, highest completed (%)
   Up to compulsory 11 (15.7) 13 (26.5) 9 (20.5) 10 (27.8) 55 (17.5) 1778 (26.6) 
   Secondary 24 (34.3) 27 (55.1) 20 (45.5) 22 (61.1) 128 (40.6) 3063 (45.7) 
   Tertiary 26 (37.1) 4 (8.2) 13 (29.5) 1 (2.8) 93 (29.5) 1356 (20.3) 
   Other/unknown 9 (12.9) 5 (10.2) 2 (4.5) 3 (8.3) 39 (12.4)    499 (7.5) 
Exposure to hepatitis C (%) 4 (5.7) 7 (14.3) 1 (2.3) 17 (47.2) 44 (14.0)    977 (14.6) 
Chronic hepatitis B (%) 10 (14.3) 1 (2.0) 2 (4.5) 13 (36.1) 22 (7.0)    393 (5.9) 
CDC clinical stage 
   A 19 (27.1) 16 (32.7) 17 (38.6) 8 (22.2) 111 (35.2) 3423 (51.1) 
   B 24 (34.3) 18 (36.7) 17 (38.6) 17 (47.2) 93 (29.5) 1761 (26.3) 
   C 27 (38.6) 15 (30.6) 10 (22.7) 11 (30.6) 111 (35.2) 1512 (22.6)
SD, standard deviation; cART, combination anti-retroviral therapy; CDC, Centers for Disease Control and Prevention; MSM, men having sex with men; 
IDU, intravenous drug use.
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Table 3. Akaike information criteria (AIC) of time-varying Cox models 
with single exposure variables.
Variable Anus Lung Prostate Liver
CD4 Lag12 826 556 526 464
Lag24 836 555 520 458
Lag36 831 555 523 460
SMA12 Lag12 830 556 524 461
SMA12 Lag24 831 555 523 455
SMA24 Lag12 829 556 523 454
CD8 Lag12 836 553 520 468
Lag24 830 554 518 471
Lag36 835 551 522 471
SMA12 Lag12 830 554 521 468
SMA12 Lag24 833 553 522 471
SMA24 Lag12 832 554 519 469
CD4/CD8 Lag12 827 552 525 470
Lag24 822 553 524 467
Lag36 830 555 525 472
SMA12 Lag12 825 552 524 471
SMA12 Lag24 825 554 524 469
SMA24 Lag12 821 554 525 468
HIV-1 RNA Lag12 818 553 520 472
Lag24 820 550 523 470
Lag36 822 551 520 472
SMA12 Lag12 817 551 520 471
SMA12 Lag24 820 554 524 472
SMA24 Lag12 818 553 523 471
Lag12, lagged by 12 months; SMA12: simple moving average over 12 months.
Models are adjusted for age, HIV transmission group, smoking, hepatitis B and C 
statuses, education, and calendar year, and include only one exposure variable. 
Numbers in bold highlight the representations selected for analysis.
a risk factor for anal cancer, and excessive alcohol consump-
tion for liver cancer, but data on sexual behavior and alcohol 
have been collected in the SHCS only since 2000 and 2005, 
respectively, and were not considered here.
The reasons for the higher cancer incidence in PLWHIV 
differ across cancers, and include multiple factors. Several stud-
ies have shown that immunodeficiency was associated with a 
higher risk of NADM28,33–35. Some of these studies analyzed 
NADM as a single group, or as groups of infection-related and 
non-infection-related NADM. We found that immunodeficiency 
(indexed by exposure to low CD4 counts) was associated with 
anal cancer and liver cancer, but not with lung cancer or prostate 
cancer. Our results indicate that each NADM should be analyzed 
separately, rather than combining different NADM into groups.
For lung cancer, a high CD8 cell count several years prior to 
the diagnosis was a risk factor whereas a low CD4 count was 
not associated with lung cancer. Persistent CD8 cell elevation 
among HIV patients on long-term cART, a marker of immune 
senescence, is associated with inflammatory, non-AIDS related 
events such as cardiovascular, renal, respiratory, metabolic 
diseases and NADM, and with increased non-AIDS-related 
mortality36–38. Mussini and colleagues suggested that the CD4/
CD8 ratio might be a more robust marker of the immune dys-
function associated with NADM than the CD4 or the CD8 cell 
count39. Indeed, a study of US veterans living with HIV found 
that the CD4/CD8 ratio was the strongest predictor of incidence 
with CD4/CD8 ratio ratios below 1.0 associated with higher 
risk15. In contrast to the veterans study, the CD8 cell count was 
more robustly associated with lung cancer risk than either the 
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Table 4. Results from separate Cox regression models for anal, lung, prostate and liver cancer and each time-updated exposure 









HR (95%CI) P HR (95%CI) P HR (95%CI) P HR (95%CI) P
CD4 cell count (cells/µl) <0.001 0.28 0.80 0.001
Lag 12m 24m 24m 12m, 24m SMA
   <200 1 1 1 1




   350-499 0.32 (0.15-0.68) 0.27 (0.08-0.95)
   500+ 0.22 (0.11-0.46) 1.54 (0.55-4.31) 0.95 (0.38-2.36) 0.06 (0.01-0.49)
CD8 cell count (cells/µl) 0.01 0.04 0.36 0.23
Lag 24m 36m 12m, 12m SMA 12m
   <1000 1 1 1 1
   1000+ 1.90 (1.14-3.15) 1.89 (1.03-3.47) 1.34 (0.72-2.49) 0.64 (0.29-1.42)
CD4/CD8 ratio <0.001 0.17 0.93 0.015
Lag 12m, 24m SMA 12m 24m 24m
   <0.50 1 1 1 1
   0.50-0.99 0.41 (0.22-0.75) 0.99 (0.52-1.89) 0.67 (0.32-1.39) 0.51 (0.23-1.12)
   ≥1.00 0.08 (0.01-0.59) 0.29 (0.07-1.26) 1.14 (0.50-2.61) 0.18 (0.02-1.37)
HIV RNA (copies per ml) 0.06 0.13 0.70 0.66
Lag 12m, 12m SMA 24m 12m 24m
   <50 1
1b
1 1
   50-499 1.79 (0.77-4.21) 0.24 (0.03-1.79) 0.26 (0.03-1.92)
   ≥500 1.79 (0.96-3.33) 1.67 (0.86-3.25) 1.34 (0.62-2.90) 0.91 (0.39-2.11)
Bacterial pneumonia 
(lagged 12m)
na 0.03 na na
   No 1
   Yes 3.23 (1.13-9.24)
a estimate for CD4 cell count 200-499 cells/µl. b the reference category is <500 HIV RNA copies per ml. 
HR, hazard ratio; CI, confidence interval; SMA, simple moving average; na, not applicable. Models for anal and liver cancer are adjusted for age, HIV 
transmission group, smoking, hepatitis B and C status, education, and calendar period. Models for lung cancer are stratified by age and adjusted for HIV 
transmission group, smoking, hepatitis C status, education, and calendar period. Models for prostate cancer are stratified for age and adjusted for HIV 
transmission group, smoking, hepatitis B and C status, education, and calendar period.
CD4 cell count or the CD4/CD8 ratio in our analysis, suggesting 
that in the cART era, immune senescence rather than immunodefi-
ciency increases the risk of lung cancer.
A history of recurrent pneumonia was associated with lung can-
cer risk in the HIV/AIDS Cancer Match study40 and in the 
US Veterans Aging Cohort Study15. In our analyses, the time-
updated history of bacterial pneumonia was associated with lung 
cancer risk in the model adjusted for baseline variables, but 
evidence of this association disappeared after adjusting for 
CD8 count. Clearly, the most important risk factor for lung 
cancer is smoking, which in Switzerland and elsewhere is sub-
stantially more common among PLWHIV than in the general 
population41–43. Smoking was also associated with anal cancer, 
but it remains unclear whether the association is causal or 
whether smoking is a marker for unsafe sexual behavior and 
exposure to HPV. Several studies have found that smoking may 
be associated with a higher risk of HPV infection44–46.
Prostate cancer is one of the most common malignancies among 
men in Western populations, and an important cause of can-
cer death. Older age, a positive family history, black race and 
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HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Exposure variables
CD4 cell count (cells/µl) 0.002 0.03
Lag 12m 12m, 24m SMA
   <200 1 1
   200-349 0.58 (0.27-1.22)
1.15 (0.47-2.81)a
   350-499 0.33 (0.14-0.76)
   500+ 0.24 (0.10-0.61) 0.08 (0.01-0.70)
CD8 cell count (cells/µl) 0.04 0.04
Lag 24m 36m
    <1000 1 1
    1000+ 1.84 (1.02-3.30) 1.89 (1.03-3.48)
CD4/CD8 ratio 0.11 0.40
Lag 12m, 24m SMA 24m
    <0.50 1 1
    0.50-0.99 0.74 (0.36-1.52) 0.74 (0.33-1.66)




    No 1
    Yes 1.67 (0.39-7.10)
Other variables
HIV transmission group <0.001 0.01 0.66 0.64
    Other men 1 0.72 (0.23-2.24) 0.90 (0.46-1.76) 0.67 (0.24-1.87)b
    Intravenous drug use 1.05 (0.18-6.09) 3.44 (1.42-8.35) 0.41 (0.04-3.71) 1.05 (0.38-2.95)
    MSM 6.86 (1.64-28.59) 1 1 1
    Other women 4.92 (1.05-23.06) 2.34 (0.97-5.62) NA
Smoking at enrollment 0.03 0.02 0.06 0.52
    No 1 1 1 1
    Yes 2.07 (1.07-3.98) 6.50 (1.36-31.2) 1.92 (0.96-3.83) 1.41 (0.51-3.95)
Hepatitis B infection 
(positive for surface antigen 
or DNA, lagged 12m)
0.53 0.72 <0.001
    No 1 1 1
    Yes 1.36 (0.54-3.43) 0.76 (0.18-3.19) 7.86 (3.78-16.4)
Hepatitis C infection (RNA 
positive, lagged 12m)
0.23 0.14 0.58 0.002
    No 1 1 1 1
    Yes 0.39 (0.09-1.77) 0.45 (0.16-1.30) 0.53 (0.06-4.61) 4.77 (1.80-12.7)
a estimate for CD4 cell count 200-499, b estimate for other women or men
HR, hazard ratio; SMA, simple moving average; MSM, men having sex with men.
All models are adjusted for the variables shown and for age, calendar period, and highest completed education. Models for lung cancer and prostate 
cancer are stratified with respect to age.
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elevated levels of insulin growth factor (IGF)-I have been 
shown to be risk factors for prostate cancer47,48. Our results do 
not suggest that immunodeficiency or immune senescence strongly 
influence prostate cancer risk. In this context, it is noteworthy 
that prostate cancer is not consistently responsive to immune 
therapy, in contrast to other solid tumors, including lung cancer49.
Liver cancer was associated with prolonged exposure to CD4 
counts below 500 cells/µl however; chronic viral hepatitis was 
a likely cause in almost all patients developing liver cancer: 
there was evidence of chronic HBV or HCV infection in 83% of 
patients with liver cancer. HBV and HCV were both strong risk 
factors for the cancer. An explanation for the strong association 
with HBV might be hepatitis delta virus (HDV) co-infection, which 
in the SHCS is observed in about 15% of patients with chronic 
HBV infection50. HDV infection accelerates the progression of 
HBV related liver disease, including hepatocellular cancer50.
Immunodeficiency and, to a lesser extent, immune senescence 
are prevented by starting cART as soon as possible after HIV 
diagnosis36, as recommended by the World Health Organiza-
tion51. The “Universal Test and Treat” approach to HIV coupled 
with interventions to ensure adherence will likely reduce the 
incidence of some NADM. The integration of smoking cessa-
tion interventions into routine care of people living with HIV 
is another important measure52. All SHCS participants are tested 
for chronic HBV infection to guide decisions on HBV vaccina-
tion and on the inclusion antiretrovirals with activity against 
HBV in cART regimens, as recommended by guidelines53,54. 
Similarly, testing for antibodies against HCV is done at HIV 
diagnosis and annually thereafter, and there is universal access 
to direct acting anti-virus (DAA) therapy against HCV. Future 
analyses of the incidence of NADM in the SHCS will docu-
ment the impact of these measures. Of note, the effectiveness 
of anal cancer screening is unclear: the ongoing Anal Cancer/
HSIL Outcomes Research Study (ANCHOR) aims to deter-
mine whether treatment of high grade squamous intraepithelial 
lesions (HSIL) prevents anal cancer55. 
Conclusions
The importance of immunodeficiency and immune senescence, 
and of other risk factors differs across NADM, with impor-
tant implications for prevention. Immunodeficiency was an 
important risk factor for anal and liver cancer whereas immune 
senescence was associated with lung cancer and anal cancer.
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Data availability
Source data
The National Institute for Cancer Epidemiology and Registration 
(NICER) is happy to share the anonymized cancer registry 
data with eligible partners. If you wish to receive specific data 
from the NICER database, please complete the respective 
form at https://www.nicer.org/en/data/request-data/.
Underlying data
The data analyzed in this study are sensitive, having been con-
tributed by people living with HIV. Access to de-identified data 
is restricted to collaborative projects that have been submit-
ted to and approved by the Scientific Board of the SHCS. Please 
contact the SHCS at http://www.shcs.ch/contact if you are 
interested in gaining access to the study data. Sharing or linkage 
of data may require additional ethics approval.
Extended data
Files with the R code used in the analysis are provided as extended 
data, along with an explanatory document, on Open Science 
Framework
Open Science Framework: Extended data for Non-AIDS defin-
ing malignancies in the combination ART era: immunological and 
socio-behavioral risk factors (Ruffieux et al. Faculty1000research 
2019). https://doi.org/10.17605/OSF.IO/GY5VM25
This project contains the following extended data:
•    code.description final.pdf (description of R code)
•    pilot.R (initializes data preprocessing for a given cancer)
•    preprocess_SHCS.R (loads SHCS data)
•    preprocess_linkage.R (loads the cases of cancer that 
could be linked to the SHCS)
•    merge.R (appends patient-level information, creates 
dataset with one line per patient)
•    risk_factors_monthly.R (creates dataset with one line per 
month, per patient, with time-updated variables)
•    write_res_df.R (sets up data for survival analysis for a 
specific cancer)
•    cancer_counts.R (produces the number of cancers per data 
source reported in Table 1)
•    patient_characteristics.R (produces results in Table 2)
•    crude_incidence_rates.R (produces crude cancer incidence 
rates)
•    SIR_NADCs.R (produces the SMRs shown in Figure 2)
•    impute_smoking.R (multiple imputation of smoking 
variable)
•    Cox_model_selection.R (produces the AICs in Table 3).
•    risk_factors_Cox.R (Cox regression to produce results in 
Table 4 and Table 5)
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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